Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis

Table 3

Markov model input parameters for chronic ulcerative colitis.

	Transition probabilities (%)/cycle	Costs (CA$)/cycle	Utility scores/year
(A) Ongoing steroids [35, 36]		917 (±25%)	0.32 (±0.31)
(1) Response	33.92 (28.09–40.33)
(2) Unwell	57.11 (50.5–63.27)
(3) Complication	2.80 (0.56–7.63)
(4) Surgery	#
(B) Response to steroids [35]		0	0.79 (±0.21)
(1) Response	53.30 (46.81–59.67)
(2) Loss of response	#
(C) Unwell on steroids [35, 36]		917 (±25%)	0.32 (±0.31)
(1) Unwell	#
(2) Complication	2.80 (0.56–7.63)
(3) Surgery	10.00 (6.40–14.28)
(D) Steroid complication [35]		23,919 (±25%)	0.16 (±0.16)
(1) Surgery	98.00 (93.70–99.78)
(2) Death	#
(E) Surgery [37, 38]		37,159 (±25%)	0.16 (±0.16)
(1) Early response	#
(2) Complication	12.8 (8.76–17.91)
(3) Death	2.50 (0.98–5.69)
(F) Response to surgery [37, 39]		0	0.58 (±0.15)
(1) Response to surgery	85.80
(2) Surgical complication	#
(3) Chronic pouchitis (CP)	11.70
(G) Chronic pouchitis [40, 41]		8,144 (±25%)	0.32 (±0.31)
(1) Response to ADA (CP)	See Table 5
(2) Nonresponse (unwell-CP)	#
(3) ADA complication (CP)	4.20
(H) Surgical complication [38]		17,586 (±25%)	0.49 (±0.32)
(1) Hospitalization	99.50 (97.22–99.99)
(2) Death	#
(I) Adalimumab (ADA) [23]		8,144 (±25%)	0.32 (±0.31)
(1) Response to ADA	86.80 (75.74–97.86)
(2) ADA complication	3.04
(3) Nonresponse (unwell)	#
(J) Response to ADA		4,442 (±25%)	0.79–0.82
(1) Response to ADA	See Table 5
(2) ADA complication	7.88
(3) Loss of response (unwell)	#
(K) Adalimumab complications		12,059 (±25%)	0.16 (±0.16)
(1) Response to ADA	70.00
(2) Unwell on steroids	14.00
(3) Surgery	14.00
(4) Death	#
(L) Death	1	Equal to cost of corresponding health state	0

#: complement probability.